LAG3 and non-small cell lung carcinoma: Furthermore, implementing combined treatment on CIK cells before transfusion via antibodies that target PD-L1, LAG-3, TIM- 3, and CEACAM-1 might improve the efficiency of CIK therapy for individuals with NSCLC.